AnatomyOrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPsychiatry and PsychologyPhenomena and Processes
Neurotoxicity SyndromesSyndromeNeurotoxinsDown SyndromeMetabolic Syndrome XNeuronsNephrotic SyndromeSjogren's SyndromeNeuroprotective AgentsNervous System DiseasesMethamphetamineBrainTurner SyndromeAmyloid beta-PeptidesManganese PoisoningAbnormalities, MultipleMyelodysplastic SyndromesNerve DegenerationN-Methyl-3,4-methylenedioxyamphetamineCushing SyndromeChlorpyrifosCells, CulturedMethylmercury CompoundsMercury Poisoning, Nervous SystemAcute Coronary SyndromePolycystic Ovary SyndromeNervous SystemMicrogliaDose-Response Relationship, DrugWilliams Syndrome1-Methyl-4-phenylpyridiniumDopaminePeripheral Nervous System DiseasesMPTP PoisoningDiGeorge SyndromeN-MethylaspartateCell DeathRats, Sprague-DawleyHorner SyndromePrader-Willi SyndromeLong QT Syndrome1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridineCerebral CortexGuillain-Barre SyndromeHemolytic-Uremic SyndromeCompartment SyndromesDisease Models, AnimalTourette SyndromeGlutamic AcidAntiphospholipid SyndromeMutation
Cytokine release syndrome and neuroICANSSevereEncephalopathyImmuneDevelopmentalImmunotherapyAcuteToxicitiesPrognosisToxinsSymptomsExposureFactorsDiagnosisImmunotherapiesDexamethasoneTherapiesEffectsSystemicTreatmentInfusionOccurBrainDisordersSpeciesPatientsGradeDamageCellChildrenTimeTitleCommonCondition
Cytokine release syndrome and neuro2
  • More severe effects include cytokine release syndrome and neurotoxicity. (consultantlive.com)
  • Which of the following statements about cytokine-release syndrome and neurotoxicity after tisagenlecleucel infusion is correct? (ascopost.com)
ICANS8
  • Talquetamab-tgvs injection may cause severe or life-threatening central nervous system reactions called immune effector cell-associated neurotoxicity syndrome (ICANS). (medlineplus.gov)
  • CAR-T therapy may result in serious side effects including two potentially dangerous syndromes: Cytokine Release Syndrome (CRS) and Immune Cell-Associated Neurotoxicity Syndrome (ICANS). (cdc.gov)
  • Fortunately, the CRS and ICANS [immune effector cell-associated neurotoxicity syndrome] responded nicely to the tocilizumab and dexamethasone. (cancernetwork.com)
  • CAR T-cell therapies are limited by the potential to cause life-threatening toxicities, including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). (ajmc.com)
  • This chapter explores current approaches to complications including CRS (cytokine release syndrome), HLH (hemophagocytic lymphohistiocytosis), and ICANS (immune effector cell-associated neurotoxicity syndrome). (emcrit.org)
  • No dose limiting toxicities (DLTs), Grade 2 or higher cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS) or adverse events of special interest (AESI) were observed. (cellectis.com)
  • The prescribing information has a Boxed Warning for serious or life-threatening cytokine release syndrome (CRS) and life-threatening or fatal immune effector cell-associated neurotoxicity syndrome (ICANS). (ecancer.org)
  • Safety analysis demonstrated a potentially best-in-class tolerability profile with Grade ≥3 cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) in 3% (3/94) and 7% (7/94) of patients, respectively. (forextv.com)
Severe4
  • The final stage of the disorder is made up of numerous disorders, including dementia, Korsakov's syndrome, and includes severe personality change such as depression, anxiety, memory loss, and drastic change in intellect. (wikipedia.org)
  • 1 These symptoms, in combination with elevated lithium levels led to a diagnosis of severe lithium neurotoxicity due to hypovolemia-induced renal failure. (neurology.org)
  • In CAR-T, lenzilumab successfully achieved the pre-specified primary endpoint at the recommended dose in a Phase 1b study with Yescarta® in which the overall response rate was 100% and no patient experienced severe cytokine release syndrome or severe neurotoxicity. (businesswire.com)
  • Neurotoxicity: Unituxin causes severe neuropathic pain. (nih.gov)
Encephalopathy1
  • Cefepime neurotoxicity is a well-documented though underrecognized cause of encephalopathy. (psychiatrist.com)
Immune5
  • She was diagnosed with immune effector cell-associated neurotoxicity syndrome and cytokine release syndrome. (cdc.gov)
  • However, CAR-T cells can also produce some adverse events after treatment of hematological malignancies, such as cytokine release syndrome (CRS), neurotoxicity, and on-target/off-tumor toxicity, which may cause systemic immune stress inflammation, destruction of the blood-brain barrier, and even normal tissue damage. (hindawi.com)
  • Nonetheless, adverse events such as cytokine release syndrome and immune effector cell-associated neurotoxicity pose substantial challenges to CAR T cell therapy. (marketsandmarkets.com)
  • Known side effects of these approved cellular immunotherapies are cytokine release syndrome, immune-cell associated neurotoxicity syndrome, cytopenias, infections and long-lasting B cell aplasia. (deepdyve.com)
  • Some examples of therapies used in the treatment of neurotoxicity include massage, exercise and immune modulaiton. (news-medical.net)
Developmental1
  • This notion is considered from epidemiological evidence using developmental methylmercury neurotoxicity as an example. (cdc.gov)
Immunotherapy2
  • At present, the mechanism of neurotoxicity caused by immunotherapy has not been completely elucidated. (hindawi.com)
  • Continuous renal replacement therapy in cytokine release syndrome following immunotherapy or cellular therapies? (bmj.com)
Acute1
  • Humanigen believes that GM-CSF neutralization with lenzilumab also has the potential to reduce the hyper-inflammatory cascade known as cytokine release syndrome common to chimeric antigen receptor T-cell (CAR-T) therapy and acute Graft versus Host Disease (aGvHD). (businesswire.com)
Toxicities2
  • the most unique adverse events are cytokine-release syndrome and neurologic toxicities. (ascopost.com)
  • 2 Please see the Important Safety Information section below, including Boxed WARNINGS for Abecma regarding Cytokine Release Syndrome (CRS), Neurologic Toxicities (NT), Hemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome (HLH/MAS), and Prolonged Cytopenia. (drugs.com)
Prognosis1
  • The timely and accurate identification of neurotoxicity helps clinicians detect and treat these complications early, thereby enhancing treatment efficiency and improving the prognosis of patients. (hindawi.com)
Toxins1
  • Some examples of toxins that occur naturally in the brain and can lead to neurotoxicity include oxygen radicals, beta amyloid and glutamate. (news-medical.net)
Symptoms6
  • Depending on the nosological entity, the main symptoms of psychoorganic syndrome are expressed differently. (wikipedia.org)
  • Psychoorganic syndrome is a combination of various symptoms that are caused by organic changes in the brain. (wikipedia.org)
  • Reversible Posterior Leukoencephalopathy Syndrome (RPLS): Permanently discontinue Unituxin and institute supportive care for signs and symptoms of RPLS. (nih.gov)
  • Symptoms may also resemble those seen in some autoimmune conditions such as irritable bowel syndrome or rheumatoid arthritis. (news-medical.net)
  • The treatment approach to neurotoxicity is elimination or reduction of the toxic substance and therapy to relieve symptoms or provide support. (news-medical.net)
  • Cauda equina syndrome refers to a characteristic pattern of neuromuscular and urogenital symptoms resulting from the simultaneous compression of multiple lumbosacral nerve roots below the level of the conus medullaris (see the image below). (medscape.com)
Exposure3
  • Psycho-organic syndrome is typically diagnosed in individuals following 5-10 years of consistent exposure to chemicals like xylene, toluene, and styrene, which are generally found in paint, plastic and degreasing products. (wikipedia.org)
  • The term neurotoxicity refers to damage to the brain or peripheral nervous system caused by exposure to natural or man-made toxic substances. (news-medical.net)
  • The outcome of neurotoxicity depends on the duration and extent of exposure to the toxic substance, as well as the degree of neural damage. (news-medical.net)
Factors2
  • Our aim was to study the frequency of metabolic syndrome and associated factors in patients with schizophrenia. (psychiatrist.com)
  • The effects of neurotoxicity depends on various different factors such as the characteristics of the neurotoxin, the dose a person has been exposed to, ability to metabolise and excrete the toxin, the ability of affected mechanism and structures to recover and how vulnerable a cellular target is. (news-medical.net)
Diagnosis1
  • Which statement about the diagnosis and management of cytokine-release syndrome after CAR T-cell infusion is correct? (ascopost.com)
Immunotherapies1
  • Nevertheless, pharmacology progress comes with a variety of side effects, of which cytokine release syndrome (CRS) is a potential complication of some immunotherapies that can lead to multiorgan failure if not diagnosed and treated accordingly. (bmj.com)
Dexamethasone1
  • With these clinical trials and anti-BCMA bispecific antibodies, they are generally hospitalized to monitor for risk of CRS [cytokine release syndrome] as well as neurotoxicity, so in the hospital she received tocilizumab as well as dexamethasone given that she had elements of both. (cancernetwork.com)
Therapies1
  • Other conditions that may develop as a result of neurotoxicity include chronic fatigue syndrome, attention deficit hyperactivity disorder, chronic sinusitis and asthma that does not respond to therapies. (news-medical.net)
Effects2
  • All patients experienced adverse effects (AEs), with treatment-related serious AEs affecting 2 patients (16.7%), including 1 instance each of febrile neutropenia and cytokine release syndrome (CRS). (cancernetwork.com)
  • Some of the effects of neurotoxicity may appear immediately, while others can take months or years to manifest. (news-medical.net)
Systemic1
  • CRS, also known as cytokine-associated toxicity, is a systemic inflammatory response syndrome following massive cytokine release into the bloodstream. (bmj.com)
Treatment3
  • Magnesium sulfate ( Epsom Salts ) has been proposed as a treatment for Irukandji syndrome after being apparently successfully used in one case. (wikipedia.org)
  • Capillary Leak Syndrome and Hypotension: Administer required prehydration and monitor patients closely during treatment. (nih.gov)
  • Although the lesion is technically involves nerve roots and represents a "peripheral" nerve injury, damage may be irreversible and cauda equina syndrome may be a surgical emergency (see Treatment). (medscape.com)
Infusion1
  • C. Most neurotoxicity cases occurred after 8 weeks of infusion. (ascopost.com)
Occur1
  • Psychoorganic syndrome may occur at any age but is most pronounced in elderly and senile age. (wikipedia.org)
Brain1
Disorders1
  • Aside from causing movement disorders, cognitive deterioration and dysfunction of the autonomic nervous system, neurotoxicity has also been shown to be a major contributor to progressive neurological disorders such as Alzheimer's disease. (news-medical.net)
Species1
  • The neurotoxicity of small Aβ(1-42) species was observed in vivo as well as in vitro in association with increased caspase-3 activity and reduced levels of the NMDA receptor subunit NR2B. (nih.gov)
Patients6
  • Among the 170 Yescarta-treated patients evaluable for safety, Grade ≥3 cytokine release syndrome (CRS) and neurologic events were observed in 6% and 21% of patients, respectively. (gilead.com)
  • A. Cytokine-release syndrome was observed in 40% to 50% of pediatric and young adult patients with relapsed or refractory ALL and adult patients with relapsed or refractory large B-cell lymphomas. (ascopost.com)
  • B. Neurotoxicity was observed in 50% of adult patients with large B-cell lymphomas. (ascopost.com)
  • Patients were assessed for the presence of metabolic syndrome, which was defined by the criteria of the National Cholesterol Education Program. (psychiatrist.com)
  • Metabolic syndrome was found in 37% (N = 13) of the patients, and it was associated inversely with the total daily dose of, but not with any specific type of, antipsychotic drug. (psychiatrist.com)
  • The results suggest that metabolic syndrome is common among patients with schizophrenia, and it may be far more common than in general populations. (psychiatrist.com)
Grade1
  • agenT-797 can be dosed up to 1000x106 cells without lymphodepletion showing no signs of neurotoxicity and cytokine release syndrome (CRS grade ≥ 3). (advfn.com)
Damage1
  • Neurotoxicity of cyclosporine A in children with steroid-resistant nephrotic syndrome: is cytotoxic edema really an unfavorable predictor of permanent neurological damage? (springermedizin.at)
Cell1
  • Constitutional syndromes such as Down syndrome and ataxia-telangiectasia are associated with increased risk of B-cell-ALL (with CRLF2 rearrangement) and T-cell-ALL, respectively. (haematologica.org)
Children1
  • MicroRNA-124 Reduces Arsenic-induced Endoplasmic Reticulum Stress and Neurotoxicity and is Linked with Neurodevelopment in Children. (harvard.edu)
Time2
Title1
  • Title : Vibration syndrome Corporate Authors(s) : National Institute for Occupational Safety and Health. (cdc.gov)
Common1
  • The syndrome was given its name in 1952 by Hugo Flecker , after the Aboriginal Irukandji people who live in Palm Cove , north of Cairns , Queensland , Australia , where stings are common. (wikipedia.org)
Condition2